{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:47:44Z","timestamp":1792608464831,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-025-05242-x","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:18:21Z","timestamp":1761200301000},"page":"2410-2415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intraindividual evaluation of gadopiclenol and gadobenate dimeglumine in liver MRI: impact on enhancement efficiency"],"prefix":"10.1007","volume":"51","author":[{"given":"Shiva","family":"Yagobian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthur","family":"Thangasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri Devi","family":"Jalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"1","key":"5242_CR1","doi-asserted-by":"publisher","first-page":"e1580","DOI":"10.1002\/wnan.1580","volume":"12","author":"R Marasini","year":"2020","unstructured":"Marasini R, Thanh Nguyen TD, Aryal S. Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12(1):e1580. doi: https:\/\/doi.org\/10.1002\/wnan.1580.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"17","key":"5242_CR2","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/cphc.201900587","volume":"20","author":"M Fragai","year":"2019","unstructured":"Fragai M, Ravera E, Tedoldi F, Luchinat C, Parigi G. Relaxivity of Gd-Based MRI Contrast Agents in Crosslinked Hyaluronic Acid as a Model for Tissues. Chemphyschem. 2019;20(17):2204\u20139. doi: https:\/\/doi.org\/10.1002\/cphc.201900587.","journal-title":"Chemphyschem"},{"issue":"8","key":"5242_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/rli.0000000000000563","volume":"54","author":"C Robic","year":"2019","unstructured":"Robic C, Port M, Rousseaux O, Louguet S, Fretellier N, Catoen S, et al. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Invest Radiol. 2019;54(8):475\u201384. doi: https:\/\/doi.org\/10.1097\/rli.0000000000000563.","journal-title":"Invest Radiol"},{"issue":"8","key":"5242_CR4","doi-asserted-by":"publisher","first-page":"e43055","DOI":"10.7759\/cureus.43055","volume":"15","author":"E Alsogati","year":"2023","unstructured":"Alsogati E, Ghandourah H, Bakhsh A. Review of the Efficacy and Safety of Gadopiclenol: A Newly Emerging Gadolinium-Based Contrast Agent. Cureus. 2023;15(8):e43055. doi: https:\/\/doi.org\/10.7759\/cureus.43055.","journal-title":"Cureus"},{"key":"5242_CR5","doi-asserted-by":"publisher","first-page":"100503","DOI":"10.1016\/j.ejro.2023.100503","volume":"11","author":"N Iyad","year":"2023","unstructured":"Iyad N, M SA, Alkhatib SG, Hjouj M. Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review. Eur J Radiol Open. 2023;11:100503. doi: https:\/\/doi.org\/10.1016\/j.ejro.2023.100503.","journal-title":"Eur J Radiol Open"},{"issue":"9","key":"5242_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/rli.0000000000000684","volume":"55","author":"E Lancelot","year":"2020","unstructured":"Lancelot E, Raynaud JS, Desch\u00e9 P. Current and Future MR Contrast Agents: Seeking a Better Chemical Stability and Relaxivity for Optimal Safety and Efficacy. Invest Radiol. 2020;55(9):578\u201388. doi: https:\/\/doi.org\/10.1097\/rli.0000000000000684.","journal-title":"Invest Radiol"},{"issue":"5","key":"5242_CR7","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/jmri.29181","volume":"60","author":"M Bendszus","year":"2024","unstructured":"Bendszus M, Laghi A, Munuera J, Tanenbaum LN, Taouli B, Thoeny HC. MRI Gadolinium-Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs. J Magn Reson Imaging. 2024;60(5):1774\u201385. doi: https:\/\/doi.org\/10.1002\/jmri.29181.","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"5242_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/jmri.25625","volume":"46","author":"TJ Fraum","year":"2017","unstructured":"Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging. 2017;46(2):338\u201353. doi: https:\/\/doi.org\/10.1002\/jmri.25625.","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"5242_CR9","doi-asserted-by":"publisher","first-page":"e222612","DOI":"10.1148\/radiol.222612","volume":"308","author":"C Kuhl","year":"2023","unstructured":"Kuhl C, Cs\u0151szi T, Piskorski W, Miszalski T, Lee JM, Otto PM. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI. Radiology. 2023;308(1):e222612. doi: https:\/\/doi.org\/10.1148\/radiol.222612.","journal-title":"Radiology"},{"issue":"1","key":"5242_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1148\/radiol.212600","volume":"305","author":"SKI Funke","year":"2022","unstructured":"Funke SKI, Factor C, Rasschaert M, Lezius L, Sperling M, Karst U, et al. Long-term Gadolinium Retention in the Healthy Rat Brain: Comparison between Gadopiclenol, Gadobutrol, and Gadodiamide. Radiology. 2022;305(1):179\u201389. doi: https:\/\/doi.org\/10.1148\/radiol.212600.","journal-title":"Radiology"},{"issue":"2","key":"5242_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/rli.0000000000001025","volume":"59","author":"J Hao","year":"2024","unstructured":"Hao J, Pitrou C, Bourrinet P. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol. 2024;59(2):124\u201330. doi: https:\/\/doi.org\/10.1097\/rli.0000000000001025.","journal-title":"Invest Radiol"},{"issue":"5","key":"5242_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/rli.0000000000000944","volume":"58","author":"LA Loevner","year":"2023","unstructured":"Loevner LA, Kolumban B, Hut\u00f3czki G, Dziadziuszko K, Bereczki D, Bago A, et al. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial. Invest Radiol. 2023;58(5):307\u201313. doi: https:\/\/doi.org\/10.1097\/rli.0000000000000944.","journal-title":"Invest Radiol"},{"issue":"3","key":"5242_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/rli.0000000000000624","volume":"55","author":"M Bendszus","year":"2020","unstructured":"Bendszus M, Roberts D, Kolumban B, Meza JA, Bereczki D, San-Juan D, et al. Dose Finding Study of Gadopiclenol, a New Macrocyclic Contrast Agent, in MRI of Central Nervous System. Invest Radiol. 2020;55(3):129\u201337. doi: https:\/\/doi.org\/10.1097\/rli.0000000000000624.","journal-title":"Invest Radiol"},{"issue":"9","key":"5242_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/rli.0000000000000572","volume":"54","author":"P Fries","year":"2019","unstructured":"Fries P, Massmann A, Robert P, Corot C, Laschke MW, Schneider G, et al. Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength. Invest Radiol. 2019;54(9):549\u201358. doi: https:\/\/doi.org\/10.1097\/rli.0000000000000572.","journal-title":"Invest Radiol"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-05242-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-025-05242-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-05242-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:20:31Z","timestamp":1775650831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-025-05242-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["5242"],"URL":"https:\/\/doi.org\/10.1007\/s00261-025-05242-x","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support for this work from any organization. Dr. Alessandro Furlan has the following disclosures: consultant for Bayer, Ascelia Pharma, and Exact Sciences. The other authors have no financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}